2. Academic Validation
  3. Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors

Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors

  • J Med Chem. 2016 Jan 14;59(1):431-47. doi: 10.1021/acs.jmedchem.5b01651.
Youngsook Shin,  Julia Suchomel,  Mario Cardozo,  Jason Duquette,  Xiao He,  Kirk Henne,  Yi-Ling Hu,  Ron C Kelly,  John McCarter,  Lawrence R McGee,  Julio C Medina,  Daniela Metz,  Tisha San Miguel,  Deanna Mohn,  Thuy Tran,  Christine Vissinga,  Simon Wong,  Sharon Wannberg,  Douglas A Whittington 1,  John Whoriskey,  Gang Yu,  Leeanne Zalameda,  Xuxia Zhang,  Timothy D Cushing
Affiliations

Affiliation

  • 1 Department of Therapeutic Discovery, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.
PMID: 26652588 DOI: 10.1021/acs.jmedchem.5b01651
Abstract

Lead optimization efforts resulted in the discovery of two potent, selective, and orally bioavailable PI3Kδ inhibitors, 1 (AM-8508) and 2 (AM-9635), with good pharmacokinetic properties. The compounds inhibit B cell receptor (BCR)-mediated Akt phosphorylation (pAKT) in PI3Kδ-dependent in vitro cell based assays. These compounds which share a benzimidazole bicycle are effective when administered in vivo at unbound concentrations consistent with their in vitro cell potency as a consequence of improved unbound drug concentration with lower unbound clearance. Furthermore, the compounds demonstrated efficacy in a Keyhole Limpet Hemocyanin (KLH) study in rats, where the blockade of PI3Kδ activity by inhibitors 1 and 2 led to effective inhibition of antigen-specific IgG and IgM formation after immunization with KLH.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z